Displaying all 4 publications

Abstract:
Sort:
  1. Eng LL, Virik HK, Thuan LC, Sinnadurai C
    Med J Malaya, 1967 Jun;21(4):310-8.
    PMID: 4230497
    Matched MeSH terms: Anemia, Aplastic/drug therapy*
  2. Gan GG, Leong CF, Sangkar JV, Teh A, Goh KY, Cheong SK
    Med J Malaysia, 2005 Aug;60(3):311-3.
    PMID: 16379185
    Aplastic anemia is a relatively uncommon disease and conventional management options include immunosuppressive drugs and/or haematopoeitic stem cell transplantation. It is now known that the pathogenesis of aplastic anemia is immune mediated. Mycophenolate mofetil is a common immunosuppressive drug now used mainly in prophylaxis of graft rejection in organ transplant and also for prevention/treatment for graft versus host disease in haemtopoeitic stem cell transplantation. It is thought that mycophenolate mofetil may be useful in this group of patients. In this short report, mycophenolate mofetil was tried in 6 patients who had severe aplastic anemia with variable doses for a minimum duration of 9 months. The result has however not been encouraging.
    Matched MeSH terms: Anemia, Aplastic/drug therapy*
  3. Menon BS, Teh KH
    N Engl J Med, 2021 Feb 25;384(8):744.
    PMID: 33626603 DOI: 10.1056/NEJMicm2026082
    Matched MeSH terms: Anemia, Aplastic/drug therapy
  4. Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, et al.
    Int J Hematol, 2016 Oct;104(4):454-61.
    PMID: 27376944 DOI: 10.1007/s12185-016-2053-8
    Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5-3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.
    Matched MeSH terms: Anemia, Aplastic/drug therapy*
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links